RSPO1 and colorectal carcinoma: <h4>Background</h4>RSPO fusions that lead to WNT pathway activation are potential therapeutic targets in colorectal cancer (CRC), but their clinicopathological significance remains unclear.<h4>Methods</h4>We screened 1019 CRCs for RSPO fusions using multiplex reverse transcription-PCR.